Search Results 131-140 of 16767 for Selective estrogen receptor modulator

  1. Clinical trials - Oncology (Medical)

    ... receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine ...

  2. Clinical trials - Oncology (Medical)

    ... receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine ...

  3. Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer - Mayo Clinic

    Hormone therapy using anastrozole and goserelin acetate may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving MK-2206, anastrozole, ...

  4. Oncology (Medical) - Clinical trials

    ... receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine ...

  5. Atenolol for the Prevention of Osteoporosis (APO) - Mayo Clinic

    bisphosphonates (within the past 3 yrs) denosumab, romosozumab, estrogen therapy or treatment with a selective estrogen receptor modulator, or teriparatide ...

  6. A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer - Mayo Clinic

    ... hormone receptors (estrogen receptor [ER] or progesterone receptor [PgR]) by immunohistochemistry (IHC). Estrogen receptor and PgR assays are considered ...

  7. Talk to your healthcare professional about these strategies to reduce the risks of menopause hormone therapy: Find the best product type for you.

  8. Clinical trials - Oncology (Medical)

    ... receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine ...

  9. Chemotherapy For Breast Cancer Clinical Trials - Mayo Clinic Research

    The treatment for postmenopausal women diagnosed with hormone receptor positive (HR+) metastatic breast cancer (mBr) includes endocrine therapy However, de novo ...

  10. A Study to Evaluate Estetrol to Treat Moderate-to-Severe Vasomotor Symptoms in Postmenopausal Women - Mayo Clinic

    8 weeks before screening start for oral estrogen and/or progestin products and/or selective estrogen receptor modulator therapy; 4. 8 weeks before screening ...